Early safety check for diabetes drug in patients with liver damage
NCT ID NCT07193147
Summary
This early-stage study aims to understand how a potential diabetes drug, GZR4 Injection, is processed by the body in people with varying degrees of liver impairment. It will enroll 36 adults, including those with mild, moderate, or severe liver damage, as well as people with normal liver function. The main goal is to measure drug levels in the blood and check for safety issues after a single dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Linyi, Shandong, 276000, China
Conditions
Explore the condition pages connected to this study.